Accelerated Bookbuild Offering

SEK 1.11 billion
Joint Bookrunner
;

Oncopeptides

Joint Bookrunner

Kempen & Co acted as Joint Bookrunner in Oncopeptides’ SEK 1.11bn capital increase

Transaction highlights

  • Placement of 7,000,000 new shares, representing c. 10% of Oncopeptides’ outstanding share capital, at an offer price of SEK 158 per share generated gross proceeds of SEK 1.11 billion (c. EUR 110m / USD 130m) 
  • Offer price represents a discount of 4.8% vis-à-vis the closing price prior to transaction announcement on 9 March 2021
  • Proceeds will be used to commercially launch PEPAXTO (also known as melflufen) in the US following recent FDA approval, and, subject to EMA approval, commercial launch in Europe
  • Furthermore, proceeds will be used for the continued clinical development within multiple myeloma, expansion into new indications and pre-clinical development of new drug candidate based on Oncopeptides’ peptide-drug conjugate platform
  • The transaction attracted interest from a large number of domestic as well as international institutional investors and sector specialists, including Artisan Partners, Bain Capital Public Equity, LP and HealthCor Management
  • Following our Joint Bookrunner role in May 2020, we are proud to have assisted this repeat client in raising approximately SEK 2.5 billion in less than a year
  • In 2021 year to date, Kempen & Co has already executed 8 transactions for European life sciences companies 

Company description

Oncopeptides is a pharmaceutical company that develops pharmaceuticals for the treatment of cancer. Its lead product candidate is PEPAXTO (also known as melflufen), a novel peptide conjugated alkylator for the treatment of hematological cancer multiple myeloma, recently got approved by the FDA for commercial use in the US. Oncopeptides is developing a host of different drug candidates across a variety of indications.

Background Kempen & Co Life Sciences & Healthcare

In the last twelve months, Kempen & Co has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include:

  • Joint Global Coordinator and Joint Bookrunner in the SEK 962 million Capital Increase by BioInvent
  • Joint Global Coordinator and Joint Bookrunner in the €22.5 million Capital Increase by Sequana Medical
  • Co-Manager in the USD 115 million US Public Offering by Y-mAbs Therapeutics
  • Co-Manager in the USD 115 million US Public Offering by Autolus Therapeutics
  • Co-Manager in the USD 165 million Nasdaq Initial Public Offering by Pharvaris
  • Passive Bookrunner in the USD 518 million US Public Offering by CureVac
  • Lead Manager in the USD 120 million US Public Offering by Merus 
  • Financial Adviser to DCprime in its merger with Immunicum 
  • Joint Bookrunner in the SEK 564 million Capital Increase by Cantargia
  • Sole Financial Adviser in the sale of Galapagos’ service operation, Fidelta, to Selvita for a total consideration of €31.2 million
  • Placement Agent in Investinor’s Secondary Sell-Down of c. 4 million shares in Calliditas Therapeutics
  • Lead Manager in the USD 85.0 million Nasdaq Initial Public Offering by Galecto
  • Joint Bookrunner in the €31.0 million Capital Increase by Sensorion
  • Bookrunner in the USD 245 million Nasdaq Initial Public Offering by Curevac
  • Co-Manager in the USD 49.0 million US Public Offering by Centogene
  • Joint Bookrunner in the SEK 1.11 billion Capital Increase by Hansa Biopharma
  • Joint Bookrunner in the CHF 80.2 million Capital Increase by Molecular Partners
  • Co-Manager in the USD 690 million US Public Offering by Ascendis Pharma
  • Financial advisor in Immatics’ business combination with Arya Sciences Acquisition Corp., thereby becoming a Nasdaq listed company and securing USD 253 million
  • Joint Global Coordinator and Joint Bookrunner in the €61.8 million Initial Public Offering by Hyloris Pharmaceuticals
  • Joint Bookrunner in the €20.0 million Capital Increase by Oryzon Genomics
  • Joint Global Coordinator and Joint Bookrunner in the SEK 487 million Capital Increase by BioInvent
  • Joint Global Coordinator and Joint Bookrunner in the c. SEK 400 million Capital Increase by Immunovia
  • Co-Manager in the USD 862 million Global Offering by argenx
  • Joint Bookrunner in the SEK 1.41 billion Capital Increase by Oncopeptides

Contact

Nadine Maalouf
Kathrin Erfurth

Transactions